Q BioMed’s technology partner, Mannin Research, has entered a collaboration with McMaster University of Ontario focused on ophthalmic drug delivery and formulation for MAN-01, a first in class small molecule to treat Primary Open-Angle Glaucoma. Research will be conducted by Dr. Heather Sheardown, a leader in ophthalmic biomaterials and drug delivery.

The collaboration will explore new and improved ways of delivering Mannin’s small molecules to the eye to treat glaucoma. Using the formulation and drug delivery expertise of the Sheardown laboratory, the collaboration aims to increase the compounds’ ability to lower intra-ocular pressure to more effectively treat glaucoma.
 
Chief executive officer of Mannin Research, Dr. George Nikopoulos said, “This collaboration is extremely important for us and Q BioMed, as well as the MAN-01 program. The Sheardown lab at McMaster University specializes in ophthalmic delivery systems. As we approach our Phase I clinical trial, having the renowned expertise and experience of Dr. Sheardown and her team working with us on delivering our small molecule candidates to the eye is important to our success.”
 
Q BioMed chief executive officer Denis Corin said, “Through this collaboration, we are also exploring the use of extended and sustained release formulations with the Mannin compounds for the treatment of other vascular related diseases, such as acute kidney injury, influenza, and myocardial ischemia. We expect the ophthalmic drug delivery data from this collaboration will inform our planned Investigational New Drug (IND) application with the U.S. FDA.”